{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061579","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.815576+00:00","generated_at":"2026-06-01T23:23:02.247176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan","bullets":["Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.","Cash $8.9M at March 31, 2024; raised ~$4.4M gross via ATM sale of 1,121,793 shares in Q1.","Phase 2b ibezapolstat results: 94% eradication of fecal C. difficile at Day 3 vs 71% for vancomycin; preserved gut microbiome.","End of Phase 2 meeting with FDA in April 2024; agreement reached on Phase 3 program and NDA pathway.","EMA approved SME designation for Acurx, granting fee reductions and support for European marketing authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061579","json":"https://secwatch.observer/filing/0001104659-24-061579.json","markdown":"https://secwatch.observer/filing/0001104659-24-061579.md","text":"https://secwatch.observer/filing/0001104659-24-061579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/0001104659-24-061579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/tm2414469d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:23:02.247176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf2e6d43679d76a328c0ea8436456f6d0bd69f88","claim":"Acurx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $4.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.","evidence_excerpt":"The Company reported a net loss of $4.4 million or $0.28 per diluted share for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/0001104659-24-061579-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$4.4 million or $0.28 per diluted share"},{"label":"EPS","value":"$0.28 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}